DISCLAIMER: This guide is educational content for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Teriparatide is a prescription-only medication requiring physician supervision. Always consult with a qualified healthcare provider before initiating, modifying, or discontinuing teriparatide therapy. This content is not a substitute for professional medical judgment.
Teriparatide (brand name Forteo) is a recombinant human parathyroid hormone analogue (rhPTH 1-34) and the first FDA-approved anabolic bone-building agent for osteoporosis treatment. Unlike antiresorptive drugs that slow bone loss, teriparatide actively stimulates bone formation through intermittent subcutaneous administration.
The compound binds to PTH/PTHrP receptors on osteoblasts and their precursors, activating adenylyl cyclase and increasing intracellular cAMP. This triggers preferential osteoblast differentiation, proliferation, and survival while suppressing apoptosis—resulting in net bone formation at both trabecular and cortical sites. Continuous PTH exposure produces the opposite effect (bone resorption), which is why intermittent dosing is critical.
Teriparatide is FDA-approved for:
- Osteoporosis in postmenopausal women
- Osteoporosis in men with primary or hypogonadal bone loss
- Glucocorticoid-induced osteoporosis at high fracture risk
Cost: $800–$3,200/month (varies by region and insurance coverage)
Route: Subcutaneous injection only
Standard approved dose: 20 mcg once daily via subcutaneous injection
Typical cycle length: 24 months (maximum FDA-recommended duration)
Frequency: Once daily, preferably at the same time each day (timing affects circadian bone turnover marker rhythms)
The anabolic effect of teriparatide depends entirely on intermittent—not continuous—exposure. Daily injections with 22–24 hours between doses allow osteoblasts to respond to the PTH signal and recover. Continuous infusion or dosing more frequently than once daily shifts the mechanism toward bone resorption and osteoclast activation, defeating the therapeutic purpose.
Pen device: Teriparatide comes in a multi-dose pen delivering 20 mcg per injection.
Reconstitution: Teriparatide is supplied as a sterile, ready-to-use liquid in the pen—no reconstitution required. Each pen contains 28 days of doses (28 × 20 mcg injections).
Storage:
- Before first use: Refrigerate at 2–8°C (36–46°F)
- After first use (in-use): Room temperature, 15–30°C (59–86°F) for up to 28 days
- Do not freeze; discard if frozen
- Do not expose to heat or direct sunlight
- Keep pen in original packaging when not in use
Duration: 24 months (maximum recommended)
Dose: 20 mcg once daily
Administration timing: Morning, 30–60 minutes before food (consistent timing optimizes bone turnover synchronization)
Expected BMD improvements:
- Lumbar spine: 6.2–9.1% increase over 12 months
- Femoral neck (combined with denosumab): 4.2% vs. 0.8% with teriparatide alone
Monitoring:
- Baseline bone mineral density (DXA scan)
- Repeat DXA at 12 and 24 months
- Serum calcium, phosphate, alkaline phosphatase at baseline, 1 month, 3 months, then quarterly
- Urinary calcium (assess nephrolithiasis risk)
Success markers: ≥3% increase in lumbar spine BMD within 12 months; stabilization or reversal of vertebral fracture progression on imaging.
Duration: 8–16 weeks (variable based on fracture type and healing trajectory)
Dose: 20 mcg once daily
Timing: Begin within 2 weeks of fracture diagnosis; continue through radiological union confirmation
Expected timeline:
- Overall radiological healing time reduction: 4.54 days (vs. placebo)
- Lower limb fractures: 6.24-day reduction in union time
- Atypical femoral fractures: 1.56-month reduction in time to union; increased early bone union (RR 1.45)
Monitoring:
- Serial radiographs at weeks 4, 8, 12, 16 (or per orthopedic protocol)
- Functional assessment (weight-bearing tolerance, range of motion)
- Serum calcium weekly (elevated in 4–6 hours post-injection; typically mild and transient)
Success markers: Bridging callus formation on imaging; progression to weight-bearing status ahead of standard timeline; reduced pain and improved mobility.
Duration: 12 months
Dose: 20 mcg once daily
Expected changes:
- Marrow fat fraction reduction: 5.87% over 12 months
- Minimal effect on subcutaneous or visceral abdominal fat
- No net fat loss; may see increased BMI and whole-body fat percentage (paradoxical finding in some cohorts)
Note: Marrow fat reduction is a mechanistic effect observed in postmenopausal osteopenic women but does not translate to clinically meaningful weight loss or improved body composition for non-osteoporotic users.
Duration: 12–24 months
Dose: 20 mcg once daily
Mechanism: Animal and mechanistic studies show teriparatide slows cartilage degeneration, reduces chondrocyte apoptosis, and promotes subchondral bone remodeling; human efficacy data are minimal.
Monitoring:
- Baseline joint imaging (X-ray or MRI)
- Repeat imaging at 12 months
- Pain/function scores (WOMAC, Lequesne index)
- Serum calcium, phosphate quarterly
Important caveat: This application is speculative based on animal data and mechanistic studies. No robust human RCTs confirm efficacy for osteoarthritis as a primary outcome.
- Remove pen from storage. If refrigerated, allow to reach room temperature (15–30°C) for 15–30 minutes before use.
- Inspect pen. Verify liquid is clear and colorless; discard if cloudy, discolored, or contains particles.
- Gather supplies: Sterile 28- or 31-gauge needle, alcohol prep pad, sharps container, cotton ball or gauze.
-
Select injection site. Rotate between:
- Abdomen (2 inches lateral to navel, 1 inch above/below navel)
- Thigh (outer aspect, mid-thigh)
- Upper arm (back of arm, mid-deltoid region)
Avoid areas with bruising, hardness, or tenderness. Do not inject into the same spot within 30 days.
-
Clean site. Wipe with alcohol prep pad; allow to dry completely (5–10 seconds).
-
Prepare pen. Attach sterile needle to pen per device instructions; prime if required (typically 1–2 units to clear air).
-
Insert needle at 90° angle into subcutaneous tissue (not muscle or periosteum). Pinch skin if preferred to lift subcutaneous layer.
-
Press injection button smoothly and hold for 3 seconds to ensure full dose delivery.
-
Withdraw needle and apply gentle pressure with cotton ball or gauze for 10 seconds.
-
Dispose of needle in sharps container immediately; do not recap.
Post-Injection
- Timing: Inject at same time daily (morning preferred to align with circadian bone turnover peaks).
- Food: Avoid eating for 30–60 minutes post-injection (enhanced absorption on empty stomach).
- Activity: Light activity (walking) is safe; avoid strenuous exercise for 2 hours.
- Monitoring: Note any injection site reactions (erythema, swelling, bruising) and report persistent reactions to provider.
- Dose: 20 mcg once daily (days 1–28)
- Timing: 7 AM, 30 minutes before breakfast
- Monitoring: Baseline labs (serum calcium, phosphate, alkaline phosphatase, 24-hour urinary calcium); record baseline DXA results
- Observations: Nausea possible (8–14% incidence); mild orthostatic hypotension, leg cramps; symptoms typically subside within 2–4 weeks
- Dose: Continue 20 mcg once daily
- Observations: Nausea usually resolves; hypercalcemia transient, peaking 4–6 hours post-injection (remain mild in most patients)
- Monitoring: Repeat serum calcium at week 8 and week 12; adjust fluid/dietary calcium if hypercalciuria develops
Months 4–12: Mid-Cycle Maintenance
- Dose: 20 mcg once daily (no escalation)
- Monitoring: Serum calcium, phosphate monthly; quarterly labs thereafter; assess for persistent leg cramps or musculoskeletal pain
- Expected sign of efficacy: Bone turnover markers (P1NP, CTX) begin to rise within weeks, peaking by month 3
- Imaging: Repeat DXA scan; confirm ≥3% lumbar spine BMD improvement
- Labs: Comprehensive metabolic panel, calcium, phosphate, alkaline phosphatase
- Continue: Yes—maintain 20 mcg daily if tolerating well and showing response
- Dose: 20 mcg once daily
- Monitoring: Every 3 months (labs); DXA at month 24 (final scan before potential cycling off)
- Watch for: Cumulative nausea, persistent leg cramps, hypercalcemia signs (polyuria, polydipsia, constipation, confusion)
Post-24 Month: Off-Cycling & Transition
- Standard approach: Discontinue teriparatide after 24 months (FDA maximum duration)
- Transition therapy: Begin antiresorptive agent (alendronate, denosumab, risedronate) to consolidate bone gains
- Rationale: Teriparatide gains plateau and may partially reverse after discontinuation if not maintained with antiresorptive therapy
- Monitoring: DXA at 12 months post-discontinuation to assess stability
- Injection site: Mild erythema, swelling, or bruising (common)
- Systemic: Nausea (onset 2–4 hours post-injection, mild-moderate); transient lightheadedness or orthostatic symptoms upon standing
- Lab findings: Serum calcium begins to rise; ionized calcium peaks 4–6 hours post-injection
- Gastrointestinal: Nausea typically resolves as body acclimates
- Musculoskeletal: Leg cramps (calf, foot) may emerge; usually mild to moderate
- Metabolic: Serum calcium stabilizes; mild hypercalciuria may develop
- Lab findings: P1NP (bone formation marker) rises significantly; alkaline phosphatase begins to increase
- Efficacy signs: Bone turnover markers (P1NP, CTX) peak; anabolic response in full effect
- Symptoms: Side effects typically plateau or resolve; most patients well-tolerated by month 3
- Functional: Early fracture cases may show bridging callus on imaging
- BMD: Progressive increases in lumbar spine (6.2–9.1% total) and femoral neck density
- Fracture healing: Complete radiological union in accelerated fracture healing protocols
- Bone quality: Improved trabecular structure, cortical thickness, and toughness on advanced imaging
- Systemic effects: Sustained anabolic state; minimal side effect burden in compliant patients
- BMD plateau: Continued modest increments; response may plateau or plateau by month 18–20
- Efficacy ceiling: Maximum anabolic response typically achieved by month 12; months 13–24 consolidate and maintain gains
- Cumulative effects: No evidence of increased toxicity with extended duration; hypercalcemia remains mild and transient
Post-Discontinuation (6–12 Months)
- Bone density: Initial partial reversal of teriparatide gains (typically 25–50% loss) if not maintained with antiresorptive therapy
- Fracture protection: Reduced fracture risk persists for years even after drug discontinuation
- Bone quality: Structural improvements (trabecular, cortical) persist longer than density gains
Error: Increasing to twice-daily dosing or 10 mcg twice daily in attempt to accelerate results.
Why it fails: Continuous or high-frequency PTH exposure shifts the mechanism from anabolic to catabolic, activating osteoclasts and promoting bone resorption. Efficacy is dose-independent above 20 mcg once daily in osteoporosis; only intermittent timing matters.
Correction: Strict once-daily dosing; no dose escalation beyond 20 mcg.
Error: Discontinuing teriparatide at month 24 without initiating antiresorptive agent.
Why it fails: Bone gains partially reverse within 6–12 months without maintenance therapy; fracture risk rises again.
Correction: Begin alendronate, risedronate, or denosumab at month 24 to consolidate and maintain teriparatide-induced density gains.
Error: Injecting repeatedly into same site or clustering injections within small area.
Why it fails: Lipohypertrophy, fibrosis, and poor absorption; erratic pharmacokinetics and unpredictable serum calcium spikes.
Correction: Rotate between abdomen, thighs, and upper arms systematically; minimum 30-day interval before re-using same site.
Error: Varying injection time daily (7 AM one day, 5 PM the next).
Why it fails: Disrupts circadian synchronization of bone turnover markers (βCTX, P1NP, ionized calcium); reduces efficacy and increases side effect variability.
Correction: Inject at identical time daily (morning preferred); if dose is missed, resume next day at normal time (do not double-dose).
Error: Starting teriparatide without baseline serum/urinary calcium, phosphate, or creatinine.
Why it fails: Cannot detect hypercalcemia, hypercalciuria, or renal impairment worsening; risk of nephrolithiasis or acute kidney injury missed.
Correction: Baseline labs at initiation; repeat at 1, 3, 12 months, and quarterly thereafter. Assess 24-hour urinary calcium at baseline and 1 month.
Error: Administering to patients with Paget's disease, prior skeletal radiation, hypercalcemia, or pediatric patients.
Why it fails: Increased osteosarcoma risk (boxed warning); worsening of underlying condition.
Correction: Screen contraindications strictly; teriparatide is contraindicated in all listed populations.
Error: